Viking Therapeutics (VKTX) announced that results from the company’s Phase 2b clinical trial of VK2809, the company’s novel liver-selective thyroid hormone receptor beta agonist, in patients with ...
There aren't many biotechs that are more exciting than Viking Therapeutics (NASDAQ: VKTX) right now. Thanks to its ...
Analysts Predict a $102 Target for Viking Therapeutics Inc (VKTX) Stock—What Could Drive It There?
On Friday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $49.58 which represents a decrease of $-3.99 or -7.45% from the prior close of $53.57. The stock opened at $53.18 and ...
Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's ...
On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $60.6 which represents a decrease of $-2.37 or -3.76% from the prior close of $62.97. The stock opened at $62.46 and ...
Equity markets have performed well in 2024, but their showing pales next to that of Viking Therapeutics (NASDAQ: VKTX), a mid ...
Did Viking Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - VKTX ...
Los Angeles Capital Management LLC trimmed its holdings in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by ...
In trading on Tuesday, shares of Viking Therapeutics Inc (Symbol: VKTX) crossed below their 200 day moving average of $61.13, changing hands as low as $58.39 per share. Viking Therapeutics Inc ...
There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback